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With increasing resistance to current antibiotics and reduced investment in the development of new antimicrobial drug classes, The World Health Organization has warned that we are at risk of entering a "post-antibiotic era" ([@B1]). The search for novel therapies to treat infectious diseases is urgent and has led to increased research to develop host-directed therapy (HDT) strategies. Successful pathogens create a hospitable environment within the host and suppress host defenses by altering cellular regulation mechanisms. HDT interventions are intended to enhance microbial killing and lessen detrimental inflammation and tissue damage by targeting host regulatory molecules and pathways modulated by pathogenesis. Preclinical studies have identified drugs with promising HDT benefits ([@B2]). The identification of these first-generation HDTs, done primarily in the context of *Mycobacterium tuberculosis* (Mtb) infection, was mainly on an empirical basis. Choosing next-generation HDT candidate agents for evaluation needs to be based on knowledge of the host regulatory signaling pathways that are disrupted by pathogens and identifying specific pathway molecules that can be therapeutically targeted.

Oncology has addressed similar challenges, i.e., reversing disruptions in cell regulatory mechanism that cause malignancies and often lead to suppression of immune processes. In response, oncologic research has developed innovative therapeutic approaches based on discoveries of basic pathogenic mechanisms of malignancies ([@B3]). These strategies include "precision medicine" (targeted reversal of cell pathway disruptions caused by mutations as pathogenic drivers) and novel "immuno-oncology" interventions, e.g., immune checkpoint reversal. The same knowledge, tools, and interventions now revolutionizing oncology can be adapted for improved therapy of many infections. These discoveries provide the infectious disease community with a roadmap for possible re-purposing of innovative HDT strategies.

Precision Medicine---Molecularly Targeted Therapies to Reverse Effects of Microbial Pathogenic Drivers Disrupting Key Regulatory Pathways of Infected Cells {#S2}
===========================================================================================================================================================

The fundamental principle of precision medicine, to develop interventions specifically targeted at disrupted human cell regulatory control mechanisms, is applicable to infectious diseases. However, the necessary research to utilize these advances for infections has not yet been widely pursued. Quoting Dr. Francis Collins (Director, National Institutes of Health) concerning precision medicine in a commentary, "A New Initiative on Precision Medicine" "... this new understanding of oncogenic mechanisms has begun to influence risk assessment, diagnostic categories, and therapeutic strategies, with increasing use of drugs and antibodies designed to counter the influence of specific molecular drivers. Many targeted therapies have been (and are being) developed, and several have been shown to confer benefits, some of them spectacular." ([@B4]) Pathogens produce their own "molecular drivers" that enhance their survival by subverting host cell regulatory signaling pathways to modify cell metabolism, functions, and internal environment to their advantage. These pathways are critical for maintaining essential functions of cells, including all immune cells. As one example, poly-ADP ribose polymerase activity is targeted by several pathogens including *Helicobacter pylori, Trypanosoma cruzi*, and HIV to enhance their survival ([@B5], [@B6]). Some pathogens also cause epigenetic modifications in infected cells, resulting in longer-term alterations in gene expression. For example, Chlamydia, Legionella, and Mtb possess DNA methyltransferases that decrease expression of immune cell genes critical for effective host defense ([@B7]).

Research evaluating the role metabolism plays in controlling immune functions (immunometabolism) has dramatically improved understanding of immune cell differentiation and regulation and lead to identification of novel immunotherapies. In immune cells, AMP-activated protein kinase (AMPK), sirtuins (SIRT), hypoxia-inducible factor-1α (HIF-1α), and mechanistic target of rapamycin (mTOR) are examples of signaling molecules that are essential "metabolic checkpoints" conserved in some form among all eukaryotic cell lineages. They regulate switches between highly active (aerobic glycolysis) and quiescent (oxidative phosphorylation, particularly of fatty acids) metabolic states ([@B8]). Other critical immune cell metabolic pathways include those involving the tricarboxylic cycle, glutamine, fatty acid synthesis, amino acids, and pentose phosphate ([@B9]). Metabolites, including succinate, produced by these metabolic pathways regulate immunometabolism in tandem with signaling molecules to affect immune activity ([@B10]). These metabolic switches occur during differentiation and maturation of many immune cell lineages and facilitate transitions between various functional states, for example, between inflammatory M1 macrophages and anti-inflammatory M2 macrophages, effector and memory CD8^+^ T lymphocytes, and Th1/Th17 versus Th2 CD4^+^ T cells.

Intracellular pathogens target these metabolic switches to suppress immune function (Figure [1](#F1){ref-type="fig"}A). HIF-1α, as a master regulator of hypoxia, plays an important role in regulating inflammation during chronic infection. Pathogens such as *Francisella tularensis* and *Pseudomonas aeruginosa* downregulate HIF-1α to inhibit glycolysis and with it inflammatory cytokine production ([@B11], [@B12]). *Streptococcus pyogenes* and Mtb both produce glycohydrolases that deplete nicotinamide adenine dinucleotide (NAD^+^), a key metabolite in macrophage function ([@B13], [@B14]). Additionally, these metabolic switches are targeted by pathogens to re-program host cellular metabolism to meet their nutritional requirements ("pathometabolism") ([@B15]). *Leishmania infantum* utilizes host cell SIRT-1 and AMPK energy sensors to switch cell metabolism from glycolysis to oxidative phosphorylation, a requirement for *L. infantum* survival ([@B16]). Other intracellular parasitic infections, including malaria and *Toxoplasma gondii* induce HIF-1α to regulate glycolytic activity and suppress macrophage proliferation ([@B17]). Virulent Mtb causes macrophages to differentiate into foam cells by blocking the glycolytic pathway ([@B18]).

![Pathogenic modulation of immunometabolic activity alters all aspects of immune function and pathogen survival. **(A)** Within an infected cell, pathogens possess "molecular drivers" (e.g., lipoproteins and glycolipids) that can modulate signaling of key regulatory pathways (e.g., ERK, AMP-activated protein kinase (AMPK), mechanistic target of rapamycin (mTOR)) involved in energy metabolism. By affecting the metabolic activity of the infected cell, pathogens alter the immune response contributing to their survival. **(B,C)** Pathogens can also modulate uninfected immune cells in the microenvironment. **(B)** By inducing persistent CD4^+^ T cell activation, pathogens cause increased PD-1 expression on CD4 T cells as well as its ligands (e.g., PD-L1) producing an exhausted T cell response. Changes in metabolic activity that occur during both persistent T cell activation and PD-1 signaling significantly contribute to T-cell exhaustion. **(C)** Suppressor cells \[e.g., Tregs, myeloid-derived suppressor cells (MDSCs)\] are recruited and activated by infected macrophages through the release molecules that include death-associated molecular patterns and pathogen associated molecular patterns (PAMPs) (e.g., HMGB-1, lipoproteins). Suppressor cells produce an immunosuppressive environment through the production of mediators (e.g., ROS, indoleamine-pyrrole 2,3-dioxygenase, and arginase) that induce oxidative stress, apoptosis, and alter immunometabolic activity.](fimmu-08-00688-g001){#F1}

Drugs targeting these checkpoint molecules, originally designed for treating cancer or metabolic syndromes, are now being tested as HDTs for pathogens. Metformin, largely through an AMPK-dependent pathway, lessens tuberculosis lung pathology by reducing chronic inflammation and tissue pathology and improves bacterial clearance in an animal model ([@B19]). Statins have both antimicrobial effects by modulating the ability of pathogens to utilize host cholesterol and immunopotentiating effects, for example, against *Leishmania* ([@B20], [@B21]). In addition to post-infection therapeutics, targeting these molecules and metabolites may also improve vaccine effectiveness through epigenetic changes and trained immunity ([@B22]--[@B24]). A thorough, though not complete list of candidate HDT agents for infections (all orally administered, non-cytotoxic, and almost all FDA-approved or in clinical trials) has recently been published ([@B25]).

Tissue destruction caused by excess inflammation and septic shock are detrimental components of immune responses to severe infections. By targeting signaling molecules such as Akt and mitogen-activated protein kinases to cause immunometabolism and epigenetic modifications, several pathogens including *H. pylori* and *Salmonella* can increase inflammation and necrosis while inhibiting autophagic and apoptotic pathways ([@B26], [@B27]). Agents to enhance autophagy and apoptosis while decreasing necrosis could improve microbial killing and decrease destructive inflammation. One key aspect of HDT target discovery research will be distinguishing between detrimental immune cell regulation changes caused by pathogen molecular drivers and adaptive changes that assist host defense. In some cases, targeted interventions may be used to enhance immune cell regulatory alterations in response to pathogens that result in improved defense, but not to an optimal level.

Immunotherapy---Therapeutic Strategies to Enhance Antimicrobial Immune Functions of Non-Infected Cells {#S3}
======================================================================================================

Current cancer immunotherapy interventions include targeting co-inhibitory T-cell checkpoint receptors, for example, by ipilimumab (CTLA-4) and pembrolizumab (PD-1), to reverse immune exhaustion and improve tumor responses. Various antagonists of suppressive co-receptors and agonists of stimulatory co-receptors, including OX-40 and 4-1BB, are in use or being investigated for treatment of several malignancies and to enhance cancer vaccine responses ([@B28]). The regulatory mechanisms of the metabolic and co-receptor immune checkpoints are often interrelated. PD-1 activation alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation ([@B29]). The result is increased T-cell longevity at the cost of reduced T-effector cell function. PD-1 antagonists reverse these metabolic changes. While the currently approved co-receptor checkpoint antagonist agents are antibodies, oral drugs that target other co-inhibitory receptors are either approved or in clinical development. For example, adenosine receptor antagonists, including istradefylline now in phase three clinical trials for Parkinson Disease, are being studied as an adjunctive cancer treatment ([@B30]).

Pathogens causing chronic infections may also activate inhibitory co-receptor checkpoints resulting in T-cell exhaustion and depressed adaptive immunity (Figure [1](#F1){ref-type="fig"}B). Early studies with LCMV indicated that by inhibiting PD-1, T cell exhaustion could be reversed. Further work with HIV and other chronic viral infections have shown that combination therapy against multiple co-inhibitory receptors can synergistically reverse T cell exhaustion ([@B31]). PD-1 research in the context of Mtb and other intracellular pathogens, though, presents the complexity of the roles of these co-receptors ([@B32], [@B33]). In studies with PD-1-deficient mice, inflammation and pulmonary tuberculosis growth were increased, while survival was decreased. However, *ex vivo* inhibition of PD-1 improved responses of T cells obtained from humans with pulmonary tuberculosis. Adding to the complexity is a recent study indicating that unlike the L1 ligand, the L2 ligand of PD-1 plays an essential role in establishing CD4^+^ T-cell mediated immunity in a malaria model ([@B34]). Defining the roles of immune checkpoints during different stages of infections is a major research gap. The roles of co-stimulatory immune cell receptors are also largely unexplored, but could be promising. Stimulation of the OX40 co-stimulatory receptor improved protection from BCG vaccine when administered simultaneously as a fusion protein in the murine model ([@B35]).

Also in common with malignant cells, infections induce immune suppressor cells, for example, myeloid-derived suppressor cells (MDSCs) and Tregs. These cells have several immunomodulatory effects, including downregulation of cytokine and chemokine expression, cell trafficking, antigen processing and presentation, and autophagy (Figure [1](#F1){ref-type="fig"}C). Suppressor cells utilize a variety of mechanisms, such as increased inhibitory reactive oxygen species production, disrupting metabolic activity, and inducing the expression of indoleamine-pyrrole 2,3-dioxygenase (IDO) ([@B36], [@B37]). Pathogens can activate suppressor cells by TLR signaling and death-associated molecular pattern release to improve their survival. Pathogens may also induce suppressor subsets of other immune cell types, including macrophages, neutrophils, and natural killer cells. Therapeutic approaches now utilized in oncology to target these cells include all-trans retinoic acid and inhibitors of mevalonate metabolism (bisphosphonates), IDO, and phosphodiesterase-5 ([@B38]).

The Path Forward {#S4}
================

Hotchkiss and Moldawer, in their article, "Parallels between Cancer and Infectious Disease," point out the similarities in changes in regulation of immune responses to malignancies and infectious pathogens that involve modulation of common signaling pathways. They also noted that immunomodulatory therapies for infections may lead to an over-reactive immune response and excess tissue damage ([@B39]). Both preclinical and clinical HDT studies must carefully address and monitor for this risk. Successful adaption of HDT for infections will require careful research to determine which patient subpopulations, types of agent, timing of initiation, and dosing regimens/duration will result in the most benefit and least harm. Development of assays to identify specific immune defects caused by specific infections, including nucleic acid- or proteomic-based detection and quantification of specific mediators of immunosuppression, would help to guide these choices and to monitor immunologic responses to HDT.

To develop such assays, the fundamental regulatory molecular disruptions causing the immunologic defects must be precisely identified. Oncologic research has utilized cutting edge tools for high throughput multiplex (genomic, epigenetic, proteomic, transcriptomic, and metabolomic) analyses of single cells from heterogeneous populations. Studies utilizing these methodologies, including CHiP analyses and DNA methylation mapping of epigenetic factors, will be essential for the identification of targets for further development as HDTs against pathogens.

Support for research to identify these specific immune cell core regulatory pathway disruptions caused by pathogens must be greatly increased to efficiently develop new HDTs for treatment and prevention. Also, drug screening methods are needed to identify which of the dozens of molecularly targeted HDT drug classes now in clinical use or evaluation for other diseases may be effective for infectious diseases. However, current screening methods using *in vitro* cell line infection models have yielded poor results. Improved *in vitro* screening models, for example, human multiple cell type-based 3-D granuloma models for TB, will need to be developed. Re-purposing of HDT drugs now in the clinic for therapy of many non-infectious diseases is a practical approach to address the lack of financial incentive to develop novel antimicrobial agents due to the high cost and lengthy development time needed for marketing approval of new drug classes versus limited financial return.

As pointed out by Dr. Collins, one goal of the precision medicine initiative is to "... instigate the next generation of scientists to develop novel approaches to be applied to a wide range of diseases with multidisciplinary approaches" ([@B4]) In order to develop innovative new HDTs for infectious diseases, such multidisciplinary teams of researchers will be needed with expertise in microbiology/clinical infectious diseases, classical immunology, and the still emerging field of molecular biology of cell regulation. The first step in this process is to facilitate collaboration among researchers studying key regulatory signaling pathways and targeted interventions for non-communicable diseases and those in the infectious diseases community. These approaches would create a transformative new paradigm for the treatment and prevention of a wide variety of infectious diseases and have a high global health impact, particularly in the face of progressive development of antimicrobial resistance. However, without meaningful financial support, the pace of development of such crucial research collaborations and the application of these innovative life-saving advances to infectious diseases will remain unacceptably slow.

Author Contributions {#S5}
====================

RM and RH contributed equally to the development and writing of the paper, reviewing relevant literature, and preparation of figure in the paper.

Disclaimer {#S6}
==========

This manuscript was written by one of the authors as a National Institute of Allergy and Infectious Diseases (NIAID) employee, but the views expressed in this manuscript do not necessarily represent those of NIAID.

Conflict of Interest Statement {#S7}
==============================

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

[^1]: Edited by: Alexandre Morrot, Federal University of Rio de Janeiro, Brazil

[^2]: Reviewed by: Ricardo Silvestre, University of Minho, Portugal; Hari Mohan Saxena, Guru Angad Dev Veterinary and Animal Sciences University, India

[^3]: Specialty section: This article was submitted to Microbial Immunology, a section of the journal Frontiers in Immunology
